C
entral sleep apnea (CSA) is a common form of sleep-disordered breathing in patients with congestive heart failure (CHF) 1 and is associated with increased morbidity and mortality. 2, 3 Patients with systolic dysfunction, higher end-diastolic left ventricular volumes, and a greater degree of pulmonary congestion are at increased risk of developing this form of sleep apnea. 4, 5 The negative cardiovascular effects of CSA are probably related to a combination of episodic hypoxemia, surges in arterial pressure, and frequent arousals. 6 Therapy with nasal continuous positive airway pressure (CPAP) has been shown to reduce CSA and to reverse some of its negative pathophysiologic consequences, but it is not clear whether these beneficial effects are due to the elimination of the CSA or to a direct effect of CPAP on improving cardiac function. 7 Compliance with nasal CPAP is also a problem in some patients. Thus, alternative therapy directly focused at the elimination of CSA would not only clarify the link between CSA and morbidity but also may provide a new therapy for patients who cannot tolerate nasal CPAP.
The narrow difference between eupneic Paco 2 and the hypocapnic apneic threshold is a critical determinant of the periodic breathing in patients with CHF. 8 Widening this difference by elevating the eupneic Pco 2 by administering exogenous CO 2 has been highly effective in eliminating CSA in patients with CHF 9,10 or without CHF. 11 However, the cumbersome delivery system associated with exogenous CO 2 was poorly suited for home use. The alternative of adding a small amount of dead space (DS) has been tested for its ability to stabilize the breathing pattern in patients with idiopathic CSA syndrome. 11 Since DS is able to "boost" Paco 2 with no requirement for exogenous CO 2 , this technique might be more feasible for long-term home use and, therefore, may provide an intriguing approach to therapy for CSA.
We investigated the cardiovascular and ventilatory response to various levels of DS during wakefulness and sleep in patients with CHF and CSA. The daytime DS study enabled us to determine the patient tolerance of the DS system and to titrate the amount of DS needed to normalize the partial pressure of end-tidal CO 2 (Petco 2 ). We then evaluated the effectiveness of DS in eliminating CSA along with its short-term effects on cardiac function.
Materials and Methods

Subjects
We studied eight stable male patients with CHF and recurrent CSA, who had a mean (Ϯ SE) age of 64 Ϯ 4 years and a body mass index of 29 Ϯ 2. Pulmonary function tests showed normal arterial blood gas levels (Pao 2 , 80 Ϯ 4 mm Hg; Paco 2 , 39 Ϯ 1 mm Hg; and pH, 7.4 Ϯ 0.06) and no obstructive or restrictive abnormalities (FEV 1 , 79 Ϯ 4%; FVC, 86 Ϯ 4%; and FEV 1 /FVC ratio, 80.3%). Seven patients had ischemic cardiomyopathy, and one patient had dilated cardiomyopathy. The average left ventricular ejection fraction was 26 Ϯ 3%. All patients had an apnea-hypopnea index (AHI) of Ͼ15 events per hour of sleep, with at least 75% of the events being of central origin. Seven of the eight patients were receiving therapy with angiotensinconverting enzyme inhibitors and beta-blockers. The University of Wisconsin Health Sciences Human Subjects Committee approved the study, and all patients provided informed written consent prior to entering the study.
Measurements
Ventilation was measured during wakefulness with a pneumotachograph (model 5719; Hans Rudolph; Kansas City, MO) coupled to a differential pressure transducer (Validyne; Northridge, CA). ECG was recorded using a monitor (model 78353 B; Hewlett-Packard Medical Products; Andover, MA). An automated sphygmomanometer (Dinamap, 1846SX; Critikon; Tampa, FL) was used to measure BP. 2 , were sampled from the mask and were measured by a gas analyzer (model CD-3A; AMETEK; Pittsburgh, PA), which was calibrated with known gases before and after each experiment. All the signals were recorded continuously for off-line analysis of the data.
Central apneas were identified by the absence of the excursion of the sum tracing of the calibrated inductive plethysmography (ie, tidal volume [Vt]) for at least 10 s with no movement of the rib cage or abdomen. The fraction of end-tidal CO 2 (Fetco 2 ) was used as a secondary method to confirm the plethysmographic output. Obstructive apneas were defined as the absence of Vt excursion for Ͼ 10 s in the presence of paradoxical chest wall motion. Hypopneas were defined by Ն 50% reduction in Vt with a reduction of arterial oxygen saturation (Sao 2 ) of Ͼ 4% for Ͼ 10 s.
Protocol
The DS system (Fig 1) consisted of a tightly sealed facemask attached to an adjustable plastic cylinder. The cylinder contained an inner extensible piece. The volume of the system could be increased from 400 to 800 mL by extending the inner piece. Both the cylinder and the inner piece had a relatively large diameter to avoid any resistive load.
Daytime Study: This independent evaluation of the cardiorespiratory effects of DS was performed on both the day before and the day after the nocturnal sleep study. On the morning before the nocturnal sleep study, measurement of BP, heart rate, Vt, respiratory frequency, and end-tidal gas levels were obtained during a 10-min period of quiet spontaneous room air breathing. Subjects then received DS from 200 to 600 mL in 200-mL increments. Each level of DS was used for 10 min, with baseline measurements repeated at the end of the trial.
In the morning after the nocturnal study, all subjects received an echocardiogram while breathing room air to measure baseline stroke volume and cardiac output. Then the same amount of DS as used during the nocturnal study was applied to each subject for 15 min before repeating the same echocardiographic measurements.
Nocturnal Study: Subjects underwent a nocturnal polysomnography that consisted of 30 to 60-min periods of room air breathing alternating with 30 to 60-min periods of DS breathing (Fig 2) . Each DS or room air trial was terminated by either awakening the subject when it had lasted 60 min or at the moment when the subject spontaneously awakened after at least 30 min in the same trial. Then a new trial was always started while the subject was awake. DS titration was repeated during the first portion of the night to determine the minimum amount of DS required to stabilize the breathing pattern. All subjects required DS levels between 400 and 600 mL, which was within the previously evaluated level of DS during the daytime study. At the end of each trial, throughout the night, an investigator entered the room to either add or remove the DS from the mask, which was left on the patient for the room air trial.
Statistical Analysis
During wakefulness, all cardiovascular and respiratory parameters were measured and averaged at each volume of DS and were compared by using analysis of variance with repeated measurement analysis. When the overall p value was significant, Student-Newman-Keuls post hoc tests were used to identify significant differences at each value of DS. For the nocturnal study, sleep stages and arousals were scored according to standard criteria, 12, 14 with each epoch of 30 s being assigned a single stage score. End-tidal Pco 2 was measured breath-by-breath and was averaged for the last 2-min period of stable breathing after each intervention. For each 1-min epoch of sleep recording, we measured the maximum, minimum, and mean Sao 2 as well as the oscillation of Sao 2 (ie, the difference between maximum and minimum Sao 2 values), and then we averaged each of these measurements during the room air and DS periods. The time to the return to sleep was defined as the time between the beginning of a DS or room air trial, which was always started in wakefulness, and the first 1-min epoch of any sleep stage. This time was measured and averaged for all trials and in both conditions. The comparison of measurements was made during DS breathing and non-DS breathing in non-rapid eye movement sleep using a paired t test. Values were expressed as the mean Ϯ SE.
Results
Effects of DS During Wakefulness
Ventilatory Response: Vt increased with the use of DS, while the respiratory frequency remained unchanged throughout the experiment (Fig 3) . With increasing DS, Fico 2 increased and Fio 2 decreased progressively. The Fetco 2 increased initially (increase with DS of 200 mL, 37.2 Ϯ 1.2 to 39.5 Ϯ 1.1 mm Hg) after which there was no further increase despite the incremental increase in DS. Likewise, no further decrease in Peto 2 was noted beyond the 400-mL DS level.
Cardiovascular Response: With the increase in DS of Յ 600 mL, no change was noted in heart rate (59 Ϯ 6 vs 62 Ϯ 6 beats/min) or arterial pressure (systolic BP, 116 Ϯ 12 vs 115 Ϯ 9 mm Hg, respectively; diastolic BP, 63 Ϯ 5 vs 61 Ϯ 4 mm Hg, respectively). On the morning after the nocturnal sleep study, echocardiography showed no difference between control and DS breathing in either stroke volume index (34 Ϯ 7 vs 33 Ϯ 7 mL/m 2 , respectively) or cardiac index (1.9 Ϯ 0.4 vs 1.9 Ϯ 0.3 L/min/m 2 , respectively).
Effects of DS During Sleep:
Since one subject could not sleep during either room air or DS breathing, the nocturnal study data are reported for the remaining seven patients.
During the nocturnal study, subjects spent a mean duration of 122 Ϯ 68 min breathing DS and 153 Ϯ 63 min breathing room air. Of the total DS time, 100 Ϯ 53 min was sleep time, and of the room air breathing time, 109 Ϯ 59 min was sleep time.
Sleep Quality: The average time to the return to sleep following each spontaneous or investigatorinduced awakening was much shorter with DS than with control breathing (11 Ϯ 6 vs 28 Ϯ 9 min, respectively; p Ͻ 0.01) [Fig 4] . Sleep stage distribution was not different with and without DS. Predominantly light sleep was present in both conditions, Figure 1 . The DS device. The mask is attached via a short connector to the plastic cylinder with extensible inner piece. The extensible inner piece contains a 4-cm hole in the distal end. The device can be adjusted to provide a DS of 200 to 800 mL. Figure 2 . Top, A: nocturnal polygraph of room air and DS breathing. The upper panel shows a segment of room air breathing followed by a segment of breathing through a face mask with 250 mL DS, then an additional 300 mL DS was added to the mask. In the lower panel, the mask and DS were removed, and the subject breathed room air again. The mask alone was added followed by an additional 250 mL DS. with [Fig 4] . Although all patients had a decrease in the arousal index, two patients had a very modest reduction. The persistence of arousals in one of these patients could be attributed to the emergence of obstructive hypopneas after the complete resolution of the central apneas with DS breathing. The other patient had a significant number of nonrespiratory arousals that persisted with DS despite the significant reduction in the number of his respiratory events.
Respiratory Effects: DS breathing resulted in a consistent reduction in the apnea index from 29 Ϯ 7 to 1 Ϯ 1 events per hour (p Ͻ 0.01). The AHI also was significantly reduced (43 Ϯ 7 vs 9 Ϯ 4 events per hour, respectively; p Ͻ 0.01) [Fig 1, 5] . The Petco 2 showed only a slight increase of 1.8 mm Hg during DS breathing compared to non-DS breathing (40.7 Ϯ 2.7 vs 38.9 Ϯ 2.6 mm Hg, respectively; p Ͻ 0.05). The minimum Sao 2 (93.1 Ϯ 1.0% vs 89.6 Ϯ 1.3%, respectively; p Ͻ 0.01) and mean Sao 2 (94.4 Ϯ 1.0% vs 93.5 Ϯ 1.1%, respectively; p Ͻ 0. 01) improved significantly with DS breathing, with no change in the maximum Sao 2 (95.0 Ϯ 0.9% vs 94.9 Ϯ 1.1%, respectively; p ϭ 0.47). The magnitude of oscillation in the Sao 2 was reduced with the DS breathing as well (⌬Sao 2 from maximum to minimum, 5.5 Ϯ 0.9% vs 1.8 Ϯ 0.4%, respectively; p Ͻ 0.01) [Fig 1, 6 ].
Cardiovascular Effects: DS breathing did not change the heart rate (65 Ϯ 6 vs 66 Ϯ 6 beats/min, respectively) or the number of ectopic beats (1.5 Ϯ 0.7 vs 1.9 Ϯ 0.8 events per hour) during sleep.
Discussion
The addition of 400 to 600 mL DS to patients with CHF and CSA during sleep resulted in a substantial decrease in AHIs, a reduction in the arousal index, and an improvement in sleep quality. The improvement in nocturnal breathing pattern and sleep quality was associated with a slight, but consistent, increase in Petco 2 and Sao 2 . We consider the elevation of Petco 2 as the primary mechanism underlying the DS-induced stabilization of breathing during sleep by keeping Paco 2 above the apneic threshold. The virtual elimination of periodic breathing is very likely to account for the improvement of sleep quality and oxygenation. No acute adverse effects of DS breathing on cardiovascular hemodynamics were noted in terms of heart rate, BP, stroke volume, and cardiac index. Added DS has been described as an alternative way to augment Paco 2 15 and has been used in patients with idiopathic CSA. 11 Because CSA secondary to CHF shares the same tendency toward hyperventilation as idiopathic CSA, 16, 17 a similar therapeutic effect in the present study is not surprising.
Studying CSA in patients with CHF allowed us to extend our previous observations about idiopathic CSA 11 to the examination of the cardiovascular and respiratory effects of added DS in patients with abnormal cardiac function. We also extended our previous studies by examining the dose response of DS during wakefulness, which yielded the following useful information on the potential mechanisms for the beneficial effect of DS in these patients.
First, the addition of DS resulted in an increase in minute ventilation as a result of an increase in the Vt without a change in the breathing frequency. This effect of DS on breathing pattern is consistent with other reports in the literature. 18, 19 Since there is no difference in the Vt and frequency responses to 1,000 mL DS while breathing 100% O 2 vs breathing room air, 19 the high Vt breathing patterns appear to be uniquely related to the DS itself. Normally, large breaths are an effective way to clear the DS and to facilitate the entering of fresh air into the lungs during the subsequent breath. 20 The increase in Vt without an associated increase in breathing frequency requires less respiratory muscle work 21 and smaller respiratory muscle tension 22 for a given level of Vt than if breathing frequency also increased, as is the case with other ventilatory stimulants including inhaled CO 2 . 18 -20 If breaths are large enough during DS breathing, the Fico 2 may actually be decreased if the DS is completely emptied with a large breath. In contrast, with exogenous CO 2 , large breaths are not able to further reduce the Fico 2 . Thus, while breathing with added DS, patients might subconsciously adopt large breaths to overcome the effect of DS in order to inhale less CO 2 . However, a potential adverse effect of this DS-induced increase in Vt also could occur. Since our patients were likely to have pulmonary congestion secondary to their severe left heart failure, the deep breaths induced by DS would need to overcome more elastic recoil pressure and thereby increase the work of breathing. In other words, the large breaths observed with added DS serve a useful function if heart function is normal but may be maladaptive in patients with CHF when using DS for the deliberate elevation of Paco 2 .
Second, the increase in DS was associated with a progressive increase in Fico 2 and a progressive decrease in Fio 2. However, there was no corre-sponding increase in Petco 2 or decrease in Peto 2 , even at the higher level of DS (ie, 400 and 600 mL) as would have been expected. This interesting finding was most consistent with an improvement in the matching of ventilation and perfusion. An improvement of the relationship of ventilation-perfusion (V /Q ) during DS breathing has been observed in unconscious patients who have received tracheostomies 21 and in resting anesthetized dogs. 23 In addition to its favorable effect on V /Q matching, 24 DS might also promote gas mixing by improving blood flow distribution and reducing the dispersion of the V /Q distribution. 23, 25 The improvement in gas exchange with added DS Figure 3 . Respiratory effects of DS during wakefulness. DS caused a progressive increase in Fico 2 . End-tidal Pco 2 increased at the lower level of added DS but then plateaued at the higher levels. Vt increased in response to DS, while frequency did not change. Fio 2 declined gradually with the increase in DS, while Peto 2 showed only a slight initial reduction and a minimal subsequent reduction despite a DS of 600 mL. * ϭ p Ͻ 0.05 compared to control breathing; ϩ ϭ p Ͻ 0.05 compared to the immediately previous dosage.
minimized the adverse effect on oxygenation that would have been expected in response to the increased Petco 2 . We actually found an increase in the mean and minimum Sao 2 in the nocturnal study with DS breathing. Therefore, oxygenation in patients with CSA can be expected to benefit from DS breathing as a result of the elimination of central apnea and from the improvement in gas exchange despite an associated slight increase in Paco 2 . Since hypoxia has been associated with augmented sympathetic nerve traffic and a carryover effect on arterial pressure, 26, 27 improvement in oxygenation has a potential beneficial effect on two important determinants of prognosis in patients with CHF. Finally, DS breathing improved sleep quality by decreasing the number of arousals and by shortening the sleep latency following intervention-induced awakenings. The interaction between sleep instaility and breathing instability has been welldescribed. 28, 29 Frequent arousals and sleep fragmentation often follow recurrent apneas due to the chemical and mechanical stimuli. 30 On the other hand, repeated arousals and rapid sleep-state fluctuation facilitate the occurrence of apneas and hypopneas by causing abrupt hyperventilation and consequent transient hypocapnia 31 and by their direct effect on central neural oscillation. 32 DS breathing may be able to break this cycle of instability by initially stabilizing the breathing pattern resulting in a secondary consolidation of the sleep state.
Added DS potentially could be associated with a number of adverse effects. First, DS breathing may increase ventilatory work and potentially may fatigue already compromised respiratory muscles. However, the Vt in our patients during DS breathing was actually smaller than the postapneic Vt following asphyxic stimulation during room air Cheyne-Stokes breathing (Fig 2) . The frequent arousals and the postapneic hyperpneas during CSA may cause equal or even more work of breathing than that associated with DS breathing. Nevertheless, since we did not make precise ventilatory measurements during periodic breathing while the patients were not using DS breathing, we cannot rule out the possibility of an increased workload with added DS.
Second, the elevation of Paco 2 by DS breathing could induce sympathetic excitation resulting in vasoconstriction, tachycardia, and an increase in myocardial contractility. 33 DS-induced hyperventilation also causes the acceleration of heart rate due to the pulmonary vagal inflation reflex. 34 This DS-induced cardiac stimulation might lead to poor long-term outcomes and morbidity. However, the increase in norepinephrine levels following the administration of exogenous CO 2 in previous studies 33 was associated with a greater increase in end-tidal CO 2 (in- Figure 4 . Effect of DS on sleep quality. In the left panel, the time to the return to sleep was measured from the onset at each trial, which was always started during wakefulness. The mean time to the return to sleep was much shorter with DS breathing than with control breathing (11 Ϯ 6 vs 28 Ϯ 9 min, respectively). The right panel shows the arousal index for all seven subjects. The mean arousal index decreased with DS breathing (21 Ϯ 8 vs 30 Ϯ 8 arousals per hour, respectively). * ϭ p Ͻ 0.05 compared to the control breathing.
crease, 4 mm Hg) than was seen in our present study (increase, 1.8 mm Hg) and yielded no improvement in the arousal index. 33 In the present study, DS resulted in a small increase in Petco 2 , which essentially returned the Paco 2 to normal, eupneic levels and was unlikely to produce large changes in the circulation. In fact, CO 2 usually produces multiple offsetting effects on the cardiovascular system. In addition to its excitatory effect on sympathetic neural activity, it also causes bradycardia and vasodilation by its direct action on the cardiac pacemaker and the vascular smooth muscle. 35, 36 Consequently, in healthy subjects, cardiac output and heart rate were predictably not affected by DS. 18 In patients with CHF, we did not find any significant increase in either BP or heart rate with a DS of 600 mL during the daytime study. The night study did not show any increase in heart rate or number of ectopic beats with DS application. Although we did not measure BP or sympathetic activities during the nocturnal studies, we attribute the lack of acute negative cardiovascular effects in our nocturnal study to the improvement in apnea index, sleep quality, arousal index, and oxygen saturation.
The practical use of added DS in patients with CHF is associated with several positive and negative considerations. Compared to pharmacologic treatment, the DS is more physiologic. For example, acetazolamide is a respiratory stimulant that is effective in improving the breathing of patients with CSA. 37 However, because it causes metabolic acidosis and has significant side effects, such as urinary frequency and paraesthesias, its usefulness is limited. Compared to exogenous CO 2 , DS breathing is a more convenient, natural, and safer means of providing CO 2 . Compared to CPAP, DS does not require the use of positive pressure in a tightly sealed mask, which can interfere with patient compliance. However, CPAP is able to improve left ventricular ejection fraction, which also could improve muscle strength independent of its effect on stabilizing the breathing pattern. 38 Hence, DS may be easier to use but not necessarily superior to the use of CPAP. On the negative side, the long-term effect of the elevation of CO 2 is unknown in terms of cardiovascular outcomes and patient compliance. Patients with CHF and CSA are very sensitive to wearing any device on their face. A more comfortable DS system would be needed to replace the present device. Taken together, the clinical significance of this study Figure 5 . Effect of DS on apnea and AHI. Apnea was virtually eliminated with DS (29 Ϯ 7 to 1 Ϯ 1 events per hour, respectively). The AHI was also significantly reduced (43 Ϯ 7 to 9 Ϯ 4 events per hour, respectively). * ϭ Ͻ 0.05 compared to control breathing.
remains uncertain. The approach remains experimental, and it should not be used routinely in clinical practice before a series of careful, long-term, follow-up studies are conducted. A single night study makes cardiorespiratory parameters comparable between room air and DS. The multiple trials in a randomized order avoided any artificial effect. However, the effect of DS breathing on sleep and its architecture has to be further studied in a full night setting. In summary, our study reported several important conclusions. First, added DS administered through a facemask is a practical modality with which to increase Petco 2 and to eliminate CSA in patients with CHF. Second, sleep quality improved with the stabilization of the breathing pattern. Third, no acute adverse cardiovascular effects were noted with DS administration. Long-term studies to determine the effect on cardiovascular outcomes and patient compliance are required before the DS device can be recommended for routine use in patients with CHF and CSA.
